Clinical Focus

  • Psychiatry
  • Interventional Psychiatry

Academic Appointments

  • Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Administrative Appointments

  • Assistant Training Director, Stanford General Psychiatry Residency Program (2025 - Present)
  • Director of the outpatient SAINT TMS clinical service, Department of Psychiatry and Behavioral Sciences (2025 - Present)
  • Medical Director of the Brain Stimulation Laboratory, Department of Psychiatry and Behavioral Sciences (2025 - Present)

Honors & Awards

  • Annual Chairman's Unsung Hero Award, Stanford Department of Psychiatry and Behavioral Sciences (2025)
  • Excellence in Teaching with appreciation from the first-year resident class, Stanford School of Medicine (2024)

Professional Education

  • Board Certification: American Board of Psychiatry and Neurology, Psychiatry (2023)
  • Residency: Columbia University Psychiatry Residency Program (2023) NY
  • Medical Education: Perelman School of Medicine University of Pennsylvania (2019) PA

Contact

  • Academic
    ehrie@stanford.edu
    University - Staff Department: Psych/General Psychiatry and Psychology (Adult) Position: Clinical Assistant Professor
  • Clinical (Primary)  Psychiatry 401 Quarry Rd Ste 2119 MC 5723 Stanford, CA 94305 (650) 724-9900 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5717

All Publications

  • Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy. World psychiatry : official journal of the World Psychiatric Association (WPA) Kratter, I. H., Austelle, C. W., Lissemore, J. I., Wada, M., Geoly, A., Chaiken, A., Kaloiani, I., Johnson, N., Wan, S., Kozyr, L., Makarewycz, E., Wong, B., Sridhar, M., Espil, F. M., Bassano, N., Kim, B., Ehrie, J., Maron-Katz, A., Tischler, C., Nejad, R., Batail, J. M., Phillips, A. L., Cole, E. J., Ford, T. J., Bentzley, B. S., Jo, B., Schatzberg, A. F., Spiegel, D., Rolle, C., Sahlem, G. L., Williams, N. R. 2026; 25 (1): 105-116

    Abstract

    Stanford neuromodulation therapy (SNT) is a rapid-acting, high-dose, intermittent theta-burst stimulation protocol. Although it has previously demonstrated efficacy for treatment-resistant depression (TRD) in a randomized controlled trial (RCT), replication in a larger sample is needed. Additionally, the electrophysiological effects of SNT remain unknown. Here we report results from a new double-blind, sham-controlled RCT along with electroencephalography (EEG) findings from the initial and current trials. In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT. At 1-month, remission (primary outcome) was achieved in 50.0% of active vs. 20.8% of sham participants (χ2 1,48=4.5, p=0.035), and response (secondary outcome) similarly favored active treatment (54.2% vs. 25.0%; χ2 1,48=4.3, p=0.039). Beta band EEG findings converged across trials: frontal beta power decreased significantly following active but not sham SNT in both the initial pilot study and the current trial. Additionally, beta baseline activity and post-SNT changes related to treatment efficacy in the current study. Specifically, greater post-SNT reduction in left anterior cingulate cortex (L-ACC) beta power correlated with greater clinical improvement immediately (rho=0.48, p=0.019) and 1-month after (rho=0.51, p=0.012) active SNT. Moreover, higher pre-treatment L-ACC beta power predicted greater subsequent clinical benefit from active SNT (immediate-post: β=-10.26, p=0.0042; 1-month after: β=-9.00, p=0.024). Neither of these L-ACC beta power findings was observed with sham stimulation. In sum, this study replicates SNT's therapeutic efficacy, identifies left frontal beta suppression as a potential mechanism of action, and highlights baseline L-ACC beta power as a candidate scalable pre-treatment biomarker of efficacy.

    View details for DOI 10.1002/wps.70032

    View details for PubMedID 41536095

    View details for PubMedCentralID PMC12805067

  • Evaluating Augmentation of Anti-Suicidal Effects of Intravenous Ketamine by Low Oral Doses of Opioid Receptor Partial Agonism Tucciarone, J., Bandeira, I. D., Kratter, I. H., Ehrie, J., Pankow, H., Chang, M., Hawkins, J., Blasey, C., Heifets, B., Schatzberg, A. ELSEVIER SCIENCE INC. 2025

    View details for Web of Science ID 001469569400015

  • Hope in the Face of "Futility": Considering the Full Scope of Psychiatric Treatment Options. AJOB neuroscience Austelle, C. W., Ehrie, J., Zabinski, J. S. 2024; 15 (1): 59-61

    View details for DOI 10.1080/21507740.2023.2292496

    View details for PubMedID 38207185

  • Transcranial Magnetic Stimulation in the Treatment of Positive, Negative, and Cognitive Symptoms of Psychosis CURRENT BEHAVIORAL NEUROSCIENCE REPORTS Manfredi, N., Zhang, R., Seltzberg, H., Johnson, M., Ehrie, J. 2023

    View details for DOI 10.1007/s40473-023-00262-7

    View details for Web of Science ID 001079831900001